NRX Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
NRX Pharmaceuticals, Inc. (NRXP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $34.18 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2021-05-21
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-03-31 was $34.18K, a 20.25% decline year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-12-31 was $230.31K, a 170.52% increase year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-09-30 was $81.96K, a 21.84% decline year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-06-30 was -$16.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $339.14K, a 375.37% increase from fiscal 2019.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $71.34K, a 84.67% decline from fiscal 2018.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was $465.43K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2021-03-31 | $34.18K 10-Q · filed 2021-05-21 | $264.50K derived: sum of 2 quarters · filed 2021-05-21 | $346.45K derived: sum of 3 quarters · filed 2021-05-21 | $330.46K derived: sum of 4 quarters · filed 2021-05-21 |
| 2020-12-31 | $230.31K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $312.27K derived: sum of 2 quarters · filed 2021-05-14 | $296.27K derived: sum of 3 quarters · filed 2021-05-14 | $339.14K 10-K/A · filed 2021-05-14 |
| 2020-09-30 | $81.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $65.96K derived: sum of 2 quarters · filed 2020-11-16 | $108.83K 10-Q · filed 2020-11-16 | $193.96K derived: sum of 4 quarters · filed 2021-05-21 |
| 2020-06-30 | -$16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $26.87K 10-Q · filed 2020-08-14 | $112.00K derived: sum of 3 quarters · filed 2021-05-21 | $216.86K derived: sum of 4 quarters · filed 2021-05-21 |
| 2020-03-31 | $42.87K 10-Q · filed 2021-05-21 | $128.00K derived: sum of 2 quarters · filed 2021-05-21 | $232.86K derived: sum of 3 quarters · filed 2021-05-21 | $218.94K derived: sum of 4 quarters · filed 2021-05-21 |
| 2019-12-31 | $85.14K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $189.99K derived: sum of 2 quarters · filed 2021-05-14 | $176.07K derived: sum of 3 quarters · filed 2021-05-14 | $71.34K 10-K/A · filed 2021-05-14 |
| 2019-09-30 | $104.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $90.94K derived: sum of 2 quarters · filed 2020-11-16 | -$13.79K 10-Q · filed 2020-11-16 | $209.78K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$13.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$118.65K 10-Q · filed 2020-08-14 | $104.92K derived: sum of 3 quarters · filed 2020-08-14 | $228.06K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | -$104.73K 10-Q · filed 2020-05-15 | $118.84K derived: sum of 2 quarters · filed 2020-05-15 | $241.98K derived: sum of 3 quarters · filed 2020-05-15 | $385.36K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $223.58K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $346.71K derived: sum of 2 quarters · filed 2020-03-30 | $490.10K derived: sum of 3 quarters · filed 2020-03-30 | $465.43K 10-K · filed 2020-03-30 |
| 2018-09-30 | $123.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $266.52K derived: sum of 2 quarters · filed 2019-11-14 | $241.85K 10-Q · filed 2019-11-14 | $1.16K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $143.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $118.72K 10-Q · filed 2019-08-14 | $204.39K derived: sum of 3 quarters · filed 2019-08-14 | |
| 2018-03-31 | -$24.67K 10-Q · filed 2019-05-15 | $61.00K derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $85.67K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |